Drug intelligence / Profile preview

varisacumab

Development stage: Unknown
Lead developer: Peregrine Holdings
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**Varisacumab** is a human monoclonal antibody that inhibits vascular endothelial growth factor A (VEGFA), blocking its binding to receptors and thereby suppressing tumor angiogenesis and vascular permeability. Developed initially by Peregrine Holdings Ltd. and later advanced by Oncologie and OncXerna Therapeutics, it targets solid tumors and hematologic malignancies through anti-VEGF activity similar to bevacizumab. Research-grade biosimilars and ELISA kits are available for preclinical studies, with clinical development reaching Phase 3.[1][3][15][18]

Other names: anti-VEGF antibody r84

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on varisacumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on varisacumab.

Explore the full profile